ible intervention more or less efficacious (ie 'DLI' could play a major role after T-depleted grafts than in un-manipulated transplants). The statement 'it has become possible to identify 90% of patients who will develop hematological relapse' after transplant seems too strong and could be misleading. Ninety percent of the observed patients with in-MC relapsed; it does not mean that it is possible to identify which '90%' will relapse vs the '10%' who won't, among the in-MC. Again, it does not mean that it is possible to identify 90% of the patient relapsing after transplant among the in-MC; the group 'in-MC' included only about half of the patients who eventually relapsed. It could mean that among the in-MC patients 90% could relapse.
Third, in this context is the discussion on historical control trial (HCT) and randomized controlled trial (RCT) well comprehended? Have the authors already found an answer in the ongoing 'cooperative non-randomized prospective trial' aimed to study the role of which intervention? DLI or CsA discontinuation? Or both? Discussions regarding RCT as opposed to HCT, the two interventional options, and the 'Kantian dogma' are too long. The 'way out of a conundrum' proposed by Lilford et al could be explained further in this context; the 'a priori' knowledge is taken into account and according to the Bayesian approach the trial can be analyzed as data accumulate and the probabilities of treatment effect can be incorporated and applied directly to 'the next patient'.
Overall, the conclusion appears not appropriate: the issue is not 'RCT vs HCT', but what to do in the setting of 'mixed chimerism' and how to design a study to assess the impact of early intervention in patients with in-MC after transplant. Either continuation of an 'observational trial' or an 'interventional randomized trial' comparing escalating doses of DLI, or DLI vs CsA discontinuation, or optimal timing of intervention, or a trial based on the Bayesian approach, as opposed to the conventional 'frequentist' approach, or any proposal would be expected at this point.
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